Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) research hub

A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.

This study is testing a new medicine, PG413, to see how it compares to an existing medicine called Eliquis. Both medicines are used to prevent strokes and treat blood clots. This early study helps us understand how PG413 works in healthy people.

A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers